← Back to headlines
Akari Therapeutics stock slides 21% despite WuXi XDC support
Akari Therapeutics saw its stock drop by 21% despite news that WuXi XDC is backing its drug program, indicating market skepticism or other factors at play.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
